Milestones

Milestones Image

2015:

22nd Century submits a “Modified Risk Tobacco Products” application to the FDA for the Company’s BRAND A proprietary Very Low Nicotine cigarettes.

2015:

22nd Century Group launches MAGIC Very Low Nicotine cigarettes, in Europe.

2014:

22nd Century purchases strategically important intellectual property (both patents and patent applications, including TRANSCRIPTION FACTOR Technology) from National Research Council of Canada.

2013:

22nd Century and British American Tobacco (BAT) enter into a worldwide research license agreement.

2011:

22nd Century enters into a 3-year R&D agreement with the University of Virginia.

2011:

22nd Century receives FDA clearance for an Investigational New Drug (IND) Application for X-22. 22nd Century licenses to its subsidiary, Heracles Pharmaceuticals, all rights to X-22.

2010:

NARA Institute of Science & Technology assigns to 22nd Century all patents that NARA had previously exclusively licensed to 22nd Century.

2006:

22nd Century funds 3-year R&D project at National Research Council (NRC), Plant Biotechnology Unit, Saskatoon Canada; obtains exclusive worldwide license from NRC for MPO genes and TRANSCRIPTION FACTOR Technology.

2005:

22nd Century funds two 4-year R&D projects at North Carolina State University.

2005:

22nd Century funds 4-year R&D project at NARA Institute of Science & Technology in Japan; obtains exclusive worldwide license from NARA for NBB1, A622 and MPO genes.

1998:

22nd Century Limited is founded to fund a 5-year R&D project at North Carolina State University (NCSU) on nicotine biosynthesis in tobacco; obtains exclusive worldwide license from NCSU for QPT genes and other technologies.